Marc Bosch Schips, M.D.

Català-Alemany. Hematòleg a la Vall d’Hebron. Defensor dels Panellets. Per Audacia Ad Astra

[ASH @ASH_hematology]

Cuts to @NIH grants don’t just affect clinicians and researchers– they affect patients, too. A new study shows that cancelled NIH funding led to the termination of 383 clinical trials, affecting more than 74,000 participants. Learn more: https://t.co/Emhf2cgR10
#Fight4Hematology

[Pau Abrisqueta @ab_pau]

Ampliamos equipo!
Buscamos hematólogo/a para la Unidad de Ensayos Clínicos @Hemato_Vhebron y otros proyectos científicos🩺🧪
Te apuntas?
(Contactar [email protected])

[Ahmed Kotb @AhmedKo45911157]

🧬 CD3×CD20 bispecifics in B-cell lymphoma
🔹 Odronextamab (IV) – IgG4
🔹 Mosunetuzumab (IV/SC)
🔹 Epcoritamab (SC, Duobody)
🔹 Glofitamab (IV, CD20-TCB) – high avidity, silent Fc ↓ toxicity
⚡ Engage T-cells, target B-cells → durable responses
#Lymphoma #SOHO25

[Marc Bosch Schips, M.D. @boschips]

@Hemato_Vhebron @VHIO

[Marc Bosch Schips, M.D. @boschips]

Highly educational talk by @gloria_iacoboni on how to approach Holding and Bridging therapies for CAR T-cell therapy.

Holding: Avoid Bendamustine and follow prior treatment wash-out periods that could potentially impact T-cell fitness prior to lymphoapheresis.

#SOHO2025 #SOHO

[Marc Bosch Schips, M.D. @boschips]

Bridging response is an important predictor for CAR T response, but be mindful of keeping toxicity at a minimum. Use radiotherapy when bridging is needed and is feasible for its microenvironment priming effects.
#SOHO2025 #SOHO

[Marc Bosch Schips, M.D. @boschips]

Many new trials exploring the inclusion of bispecifics into chemotherapy back-bones in the first line. Are the R-CHOP killers inbound?

[Marc Bosch Schips, M.D. @boschips]

Excellent talk by @JSALymphomaDoc guiding the current perspectives on treatment sequencing and Bispecifics use in DLBCL.
Glofit-GemOx for second line in non CAR T-cell elegible/available patients with great outcomes and a good alternative for these patients. #SOHO2025

[GELTAMO @geltamo]

@geltamo en #18ICML

IBRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY
PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LARGE B-CELL LYMPHOMAS: EXPERIENCE FROM THE GELTAMO GROUP #DavidAlonsoCastronuño #NormaGutierrez
@icmlugano

[Alfredo Rivas-Delgado @arivasdelgado]

LymphoMAPs identifies 3 microenvironmental patterns in DLBCL:
- LN: healthy T-cell rich → best CAR-T response
- TEX: exhausted T-cells → limited CAR-T benefit
- FMAC: TAMs/endothelial-rich → poor outcome to R-chemo
#18ICML

[Sandra Novoa Jauregui @NovoaJauregui]

Happy to share! Out this week in @LeukemiaJnl

👉🏾CSA germline variants in SF3B1wt RS-MDS

A @gesmd proyect in collaboration with @leukaemielabor. Thanks to all co-authors, specially @anjecayu and Julia Montoro for their mentorship! @Hemato_Vhebron

https://t.co/uPrGGBpqRT

[Andrés Jerez @anjecayu]

90 primeros días de vida del Manual de Predisposición Germinal a Neoplasia Hematológica de la SEHH: 570 visitas, 50 de nuestros compañeros de LATAM. Y “los misterios de la red”…¿qué pasó el 30 y 31 de enero para alcanzar ese pico de 60 visitas? https://t.co/xdZFpgDqjw

[Vall d'Hebron @vallhebron]

El Dr. Guillermo Orti, hematòleg de la Unitat de Trasplantament de Progenitors Hemopoètics de #VallHebron, ha participat en el #DíaMundialdelaEICR en una jornada de sensibilització al @Senadoesp per a pacients, professionals i públic en general organitzada per @AEAL_.

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔬 ¿Quieres un futuro prometedor en el ámbito clínico y la investigación en 2025?⁣

🎓 En @Hemato_Vhebron te ofrecemos una formación completa. Descúbrela aquí ➡️ https://t.co/zJDHWehvNW

🚀 ¡Haz de la hematología tu mejor opción! Te esperamos en @vallhebron 🏥

#ResisHematoVH

[Marc Bosch Schips, M.D. @boschips]

Si planteas especializarte en #Hematología, pregunta a nuestros residentes @sergicc_97, @beas_francisco por una formación de calidad con los tratamientos más innovadores en Vall d’Hebron. ⁦@VHIO⁩ ⁦@vallhebron⁩ https://t.co/eDDodj0r5J

[U.S. Surgeon General @Surgeon_General]

NEW: Today, I’m releasing a Surgeon General’s Advisory on the causal link between alcohol consumption and increased cancer risk. Alcohol is the 3rd leading preventable cause of cancer in the U.S., contributing to about 100,000 cancer cases and 20,000 cancer deaths each year.

[Ángel Serna @asernapareja]

Delighted to present our poster at #ASH2024 on behalf @geltamo

"Immunotherapy May Be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

@Hemato_Vhebron

Thanks to all the contributing authors

[Andrés Jerez @anjecayu]

Proud of @mgabarros Oral presentation addressing donor cell derived HN. Likely understimated, definitely an event we have to prevent. An effort from alloHSCT and genomic Spanish Centers.@sehh_es @VHIO @Hemato_Vhebron

[Ahmed Bennis MD 🫀 @drbennisahmed]

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve

rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months

https://t.co/zOKsXCQay0

[Mima Llompart @mima_llompart]

Primer día de #CNC2024 con presentaciones del @hospitalclinic y entrega de becas. Eternamente agradecida a la @aecirujanos y a mis mentores @m_pera_roman @dmomblan por su ayuda y apoyo incondicional ❤️